Two-level ESPB in Total Knee Arthroplasty

Poznan University of Medical Sciences (PUMS)

Status and phase: Completed; Phase 4

Conditions: Knee Arthritis; Knee Pain Chronic; Knee Osteoarthritis

Treatments: Drug: 2 x 20 ml of Ropivacaine 0.2% Injectable Solution; Drug: 2 x 20ml of Ropivacaine 0.2% Injectable Solution

Study type: Interventional

Funder types: Other

Identifiers

NCT06470542

9/2024

Details and patient eligibility

About

Effect of two-level ESPB in Total Knee Arthroplasty

Full description

Knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects.

Enrollment: 60 patients

Sex: All

Ages: 65 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients scheduled for total hip arthroplasty
• patients aged >65 and <100 years
• patients able to provide informed consent
• patients able to reliably report symptoms to the research team

Exclusion criteria

• inability to provide first-party consent due to cognitive impairment or a language barrier

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 2 patient groups

iPACK + ACB

Active Comparator group

Description:

Ultrasound-guided iPACK +ACB

Treatment:

Drug: 2 x 20 ml of Ropivacaine 0.2% Injectable Solution

Two-Level ESPB

Active Comparator group

Description:

Bi-level Ultrasound-guided ESPB et the L1 and S1

Treatment:

Drug: 2 x 20ml of Ropivacaine 0.2% Injectable Solution